Diabetes prevalence and mortality in COVID-19 patients: a systematic review, meta-analysis, and meta-regression.
Coronavirus infection
Diabetes mellitus
Diabetes mellitus, type 1
Diabetes mellitus, type 2
Journal
Journal of diabetes and metabolic disorders
ISSN: 2251-6581
Titre abrégé: J Diabetes Metab Disord
Pays: Switzerland
ID NLM: 101590741
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
07
10
2020
accepted:
20
03
2021
pubmed:
7
4
2021
medline:
7
4
2021
entrez:
6
4
2021
Statut:
epublish
Résumé
The coronavirus disease 2019 (COVID-19) patients with diabetes mellitus (DM) are at high risk of fatal outcomes. This meta-analysis quantifies the prevalence of mortality among (1) diabetic and (2) non-diabetic, and (3) the prevalence of DM, in hospitalized COVID-19 patients. Published studies were retrieved from four electronic databases (PubMed, Embase, Scopus, and medRxiv) and appraised critically utilizing the National Heart, Lung, and Blood Institute's tool. Meta-analyses were performed using the random-effects model. The measures of heterogeneity were ascertained by I- squared ( Of the reviewed 475 publications, 22 studies (chiefly case series (59.09 %)), sourcing data of 45,775 hospitalized COVID-19 patients, were deemed eligible. The weighted prevalence of mortality in hospitlized COVID-19 patients with DM (20.0 %, 95 % CI: 15.0-26.0; Hospitalized COVID-19 patients were appreciably burdened with a high prevalence of DM. DM contributed to the increased risk of mortality among hospitalized COVID-19 patients compared to non-DM patients, particularly among critically ill patients. The online version contains supplementary material available at 10.1007/s40200-021-00779-2.
Sections du résumé
BACKGROUND
BACKGROUND
The coronavirus disease 2019 (COVID-19) patients with diabetes mellitus (DM) are at high risk of fatal outcomes. This meta-analysis quantifies the prevalence of mortality among (1) diabetic and (2) non-diabetic, and (3) the prevalence of DM, in hospitalized COVID-19 patients.
METHODS
METHODS
Published studies were retrieved from four electronic databases (PubMed, Embase, Scopus, and medRxiv) and appraised critically utilizing the National Heart, Lung, and Blood Institute's tool. Meta-analyses were performed using the random-effects model. The measures of heterogeneity were ascertained by I- squared (
RESULTS
RESULTS
Of the reviewed 475 publications, 22 studies (chiefly case series (59.09 %)), sourcing data of 45,775 hospitalized COVID-19 patients, were deemed eligible. The weighted prevalence of mortality in hospitlized COVID-19 patients with DM (20.0 %, 95 % CI: 15.0-26.0;
CONCLUSIONS
CONCLUSIONS
Hospitalized COVID-19 patients were appreciably burdened with a high prevalence of DM. DM contributed to the increased risk of mortality among hospitalized COVID-19 patients compared to non-DM patients, particularly among critically ill patients.
SUPPLEMENTARY INFORMATION
BACKGROUND
The online version contains supplementary material available at 10.1007/s40200-021-00779-2.
Identifiants
pubmed: 33821206
doi: 10.1007/s40200-021-00779-2
pii: 779
pmc: PMC8012080
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
939-950Informations de copyright
© Springer Nature Switzerland AG 2021.
Déclaration de conflit d'intérêts
Conflict of interest On behalf of all authors, the corresponding author states that there is no conflict of interest.
Références
Acta Diabetol. 2010 Sep;47(3):193-9
pubmed: 19333547
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
Arch Acad Emerg Med. 2020 Mar 24;8(1):e35
pubmed: 32232218
Lancet Infect Dis. 2020 Jun;20(6):656-657
pubmed: 32199493
Clin Microbiol Infect. 2020 Aug;26(8):1063-1068
pubmed: 32251842
Diabet Med. 2006 Jun;23(6):623-8
pubmed: 16759303
J Assoc Physicians India. 2020 May;68(5):13-17
pubmed: 32610859
J Clin Epidemiol. 2009 Oct;62(10):e1-34
pubmed: 19631507
Syst Rev. 2016 Dec 5;5(1):210
pubmed: 27919275
J Diabetes Sci Technol. 2020 Jul;14(4):813-821
pubmed: 32389027
Eur Radiol. 2020 Nov;30(11):6151-6160
pubmed: 32474629
J Infect. 2020 Aug;81(2):e16-e25
pubmed: 32335169
Clin Microbiol Infect. 2020 Sep;26(9):1242-1247
pubmed: 32526275
MMWR Morb Mortal Wkly Rep. 2020 Apr 17;69(15):458-464
pubmed: 32298251
J Korean Med Sci. 2020 Jun 15;35(23):e223
pubmed: 32537957
Diabetes Care. 2020 Jul;43(7):1382-1391
pubmed: 32409504
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
BMJ Open Diabetes Res Care. 2020 Apr;8(1):
pubmed: 32345579
J Korean Med Sci. 2020 Jun 15;35(23):e209
pubmed: 32537954
JAMA. 2020 Jun 23;323(24):2493-2502
pubmed: 32392282
Arch Public Health. 2014 Nov 10;72(1):39
pubmed: 25810908
Nat Microbiol. 2020 Apr;5(4):562-569
pubmed: 32094589
N Engl J Med. 2020 Mar 19;382(12):1177-1179
pubmed: 32074444
Diabetes Res Clin Pract. 2020 Jul;165:108227
pubmed: 32446795
JAMA. 2020 May 12;323(18):1775-1776
pubmed: 32203977
J Infect Public Health. 2020 Jul;13(7):906-913
pubmed: 32546437
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Viruses. 2019 Jan 14;11(1):
pubmed: 30646565
Diabetologia. 2020 Aug;63(8):1500-1515
pubmed: 32472191
Int J Infect Dis. 2020 May;94:91-95
pubmed: 32173574
Eur Respir J. 2020 May 14;55(5):
pubmed: 32217650
Diabetes Metab Syndr. 2020 Jul - Aug;14(4):535-545
pubmed: 32408118
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
J Clin Virol. 2020 Jun;127:104354
pubmed: 32305882
PLoS One. 2020 Dec 17;15(12):e0243027
pubmed: 33332356
Front Med (Lausanne). 2020 Jun 05;7:286
pubmed: 32582740
Epidemiol Infect. 2018 Nov 05;147:e35
pubmed: 30394248
Diabetes Res Clin Pract. 2020 Jul;165:108263
pubmed: 32531325
N Engl J Med. 2020 May 21;382(21):2012-2022
pubmed: 32227758
Am J Prev Med. 2020 Aug;59(2):168-175
pubmed: 32564974
Clin Immunol. 2020 Aug;217:108509
pubmed: 32535188
J Clin Virol. 2020 Jun;127:104378
pubmed: 32353762
BMJ. 2020 May 22;369:m1985
pubmed: 32444460